Innovations in immunotherapy, including chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocyte (TIL) therapies, are emerging as promising treatments for gastrointestinal cancers. A recent comprehensive review by Sayed et al. highlights progress in engineering these therapies to target GI tumors more effectively. This immuno-oncology advancement offers hope for improved patient outcomes in a cancer type historically resistant to conventional treatments.